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ABSTRACT
In patients with Myelofibrosis (MF) treated with ruxolitinib (RUX), the response 
is unpredictable at therapy start. We retrospectively evaluated the impact of 
clinical/laboratory factors on responses in 408 patients treated with RUX according 
to prescribing obligations in 18 Italian Hematology Centers. At 6 months, 114 out 
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 45), pp: 79073-79086
                                                        Clinical Research Paper
Oncotarget79074www.impactjournals.com/oncotarget
of 327 (34.9%) evaluable patients achieved a spleen response. By multivariable 
Cox proportional hazard regression model, pre-treatment factors negatively 
correlating with spleen response were: high/intermediate-2 IPSS risk (p=0.024), 
large splenomegaly (p=0.017), transfusion dependency (p=0.022), platelet count 
<200x109/l (p=0.028), and a time-interval between MF diagnosis and RUX start >2 
years (p=0.048). Also, patients treated with higher (≥10 mg BID) average RUX doses 
in the first 12 weeks achieved higher response rates (p=0.019). After adjustment 
for IPSS risk, patients in spleen response at 6 months showed only a trend for 
better survival compared to non-responders. At 6 months, symptoms response was 
achieved by 85.5% of 344 evaluable patients; only a higher (>20) Total Symptom 
Score significantly correlated with lower probability of response (p<0.001). Increased 
disease severity, a delay in RUX start and titrated doses <10 mg BID were associated 
with patients achievinglower response rates. An early treatment and higher RUX doses 
may achieve better therapeutic results.
INTRODUCTION
Myelofibrosis (MF) is a chronic myeloproliferative 
neoplasm (MPN) primarily characterized by dysregulation 
of the JAK-STAT pathway, that is thought to be responsible 
for increased myeloproliferation and abnormal production 
of pro-inflammatory cytokines [1]. MF can present as 
primary disease (PMF) or post essential thrombocythemia 
(PET-MF) or post polycythemia vera (PPV-MF). The 
clinical hallmarks of both primary and secondary MF are 
splenomegaly, constitutional (specifically, fever, weight 
loss and night sweats) and/or disease-related (i.e. fatigue, 
pruritus and abdominal pain) symptoms, and cytopenias 
(mainly, anemia) [2, 3]. MF results in severely impaired 
quality of life and reduced survival, particularly in patients 
with high and intermediate-2 risk disease according to the 
International Prognostic Score System (IPSS) [4].
Ruxolitinib (RUX) is a potent and selective JAK1/
JAK2 inhibitor that has demonstrated superiority over 
placebo [5, 6] and over best available therapy (BAT) 
in the phase 3 Controlled MyeloFibrosis Study with 
Oral JAK Inhibitor Treatment II (COMFORT-II) trial 
[7, 8]. In this latter trial, 32% of patients randomized to 
ruxolitinib achieved ≥35% decrease in spleen volume at 
week 24 and many patients had also marked reductions in 
myelofibrosis-associated symptoms. In the first report of 
the Phase 3b expanded access JAK Inhibitor RUxolitinib 
in Myelofibrosis Patients (JUMP) trial, 62.3% of patients 
achieved a ≥50% reduction from baseline in palpable 
spleen length at 48 weeks, and around 50% of patients 
had a symptoms response according to different scales 
[9]. While extra-hematological toxicity was mild and 
infrequent, grade 3-4 anemia and thrombocytopenia were 
observed in 33% and 12.5% of patients, respectively. 
Based on these efficacy and safety data, RUX has become 
the first and still only JAK1/2 inhibitor commercially 
available for the treatment of MF. To date, treatment is 
commonly triggered by the appearance or progression 
of significant clinical needs, and there are no baseline 
features that may predict responses and help selecting 
patients who are more likely to benefit from RUX therapy.
Here, we report a large cohort of MF patients 
treated with RUX and evaluated for response according to 
the International Working Group for Myeloproliferative 
Neoplasms Research and Treatment (IWG-MRT) and 
European LeukemiaNet (ELN) criteria [10], with the 
aims to: 1) provide independent data on type and rate 
of homogeneously defined responses; 2) evaluate pre-
treatment clinical/laboratory factors associated with 
responses; 3) investigate the role of RUX doses on 
efficacy measures; 4) explore the potential association of 
spleen response with survival.
RESULTS
Study cohort
Between June 2011 and Apr 2016, 408 patients with 
PMF (n. 222, 54.4%), PET-MF (n. 113, 27.7%) or PPV-
MF (n. 73, 17.9%) were treated with RUX in 18 Italian 
Hematology Centers and were included in the study. 
Overall, 160 patients received RUX as per compassionate 
or commercial use, while 248 (60.8%) patients were 
first enrolled in the JUMP trial [9], which was closed 
for enrolment in September 2014. From January 2015 
onwards, all patients received the drug outside clinical 
trials. The total observation time was 903.5 patient-
years; the time spent in the JUMP trial accounted for 
363.2 patient-years. Patients received a re-evaluation 
of hematology parameters, marrow histology, fibrosis 
grading and karyotype before the start of RUX. Table 1 
summarizes main baseline clinical and laboratory data of 
the entire cohort. Patients treated off-study had similar 
baseline features as compared to patients first enrolled in 
the JUMP trial. However, they were more frequently at 
intermediate2/high IPSS risk (88.8% vs 81.5%, p=0.048).
Marrow fibrosis was evaluable in 378 (92.6%) 
patients and was grade 1 in 107 (28.3%), grade 2 in 163 
(43.1%), and grade 3 in 108 patients. Full molecular data 
were available for 323 patients (79.2%): JAK2V617F was 
present in 87%, CALR mutations in 8%, and MPLW515K/L 
in 1%; 4% of the patients were triple negatives. Twenty-
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four patients (5.9%) were JAK2V617F-negative but did not 
receive further molecular evaluation; in 61 (14.9%) cases, 
no molecular data was available. Most (57.9%) JAK2V617F-
positive patients were homozygous; median allele burden 
was 80% (range, 2%–99%). Median follow-up from MF 
diagnosis was 3.8 years (range, 0.3-29.2) and median 
RUX exposure was 20 months (range, 3-56.2).
Ruxolitinib doses and causes of discontinuations
RUX starting dose was 20 mg BID, 15 mg BID, 
10 mg BID and 5 mg BID in 221 (54.2%), 108 (26.5%), 
30 (7.3%), and 49 (12%) patients, respectively. Many 
(39.3%) patients had a dose modification during the 
first 12 weeks of therapy (dose decrease in 91.1% of 
the cases). Particularly, 40.6% and 41.7% of patients 
that started ruxolitinib at the dose of 15 mg and 20 mg 
BID, respectively, underwent a dose reduction at 12 
weeks. Conversely, 14.6% and 14.8% of patients that 
initiated ruxolitinib at the dose of 5 and 10 mg BID, 
respectively, were eventually able to increase ruxolitinib 
dose (Figure 1). The average daily dose was 28.3 mg 
for patients starting at 20 mg BID, 22.9 mg for patients 
starting at 15 mg BID, 17.2 mg for patients starting at 10 
mg BID, and 11.7 mg for patients starting at 5 mg BID.
Overall, 146 (35.8%) patients discontinued RUX 
after a median time of 13 months. More specifically, 32 
out of 379 evaluable patients discontinued RUX within the 
Table 1: Patients’ characteristics at ruxolitinib start 
Characteristics Patients (n. 408)
Male sex, no (%) 230 (56.4%)
Median age, years (range) 68.5 (26.5 – 89.0)
Primary Myelofibrosis, no (%) 222 (54.4%)
 Age >65 years, no (%) 259 (63.5%)
IPSS intermediate-2/high, no (%) 344 (84.3%)
Median hemoglobin, g/dl (range) 10.7 (7 – 16.7)
 Hemoglobin <10 g/dl 173 (42.4%)
Transfusion dependence, no (%) 114 (27.9%)
Median platelet, x109/l (range) 256.5 (50 – 1632)
 Platelet >200 x109/l 259 (63.5%)
 Platelet <100 x109/l 39 (9.6%)
Constitutional symptoms, no (%) 220 (53.9%)
Palpable spleen, no (%) 394 (96.6%)
 Spleen ≥10 cm, no (%) 262 (64.2%)
JAK2V617F mutation, no (% on 347 evaluable) 281 (81.0%)
Unfavorable karyotype, no (% on 212 evaluable) 17 (8.0%)
Grade 3 marrow fibrosis, no (% on 378 evaluable) 108 (28.6%)
Time from MF diagnosis to RUX start >2 years 185 (45.3%)
Mean time from MF diagnosis to RUX start, months (SD) 44.4 (58)
RUX starting dose
 5 mg BID 49 (12.0%)
 10 mg BID 30 (7.4%)
 15 mg BID 108 (26.5%)
 20 mg BID 221 (54.2%)
Karyotype was abnormal in 55 (25.9%) out of 212 evaluable patients. In 17 cases (8%) an unfavorable karyotype was 
detected, specifically: trisomy 8 (5 patients), complex (5 patients), del7 (3 patients), del5 (3 patients), and trisomy 1 
(1 patient).
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Figure 1: Proportion of patients treated with different doses of ruxolitinib over time, after stratification according to ruxolitinib starting 
doses (A: 5 mg BID; B: 10 mg BID; C: 15 mg BID; D: 20 mg BID). Percentages are calculated on evaluable patients at each time point. 
Ruxolitinib starting doses were mainly administered according to prescribing information (i.e.: 5 mg BID if platelet between 50 and 99 
x109/l, 15 mg BID if platelet between 100 and 199 x109/l, 20 mg BID if platelet ≥ 200 x109/l).
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first 6 months of therapy, 68 out of 334 evaluable patients 
within 12 months and 93 out of 308 evaluable patients 
within 18 months, for a discontinuation rate of 8.4%, 
20.4% and 30.2% at 6, 12 and 18 months, respectively. 
Reasons for RUX discontinuations were: lack of response 
(27 patients, 18.5%); loss of response (15, 10.3%); drug-
related toxicity (27.4%, specifically: 24 patients for 
thrombocytopenia, 16.4%; 9 for severe infections, 6.2%; 
7 for anemia, 4.8%); disease progression with/without 
acute evolution (13 patients, 8.9%); death (20, 13.7%); 
allogeneic transplant (13, 8.9%); second neoplasia (6, 
4.1%); other causes (12 patients, 8.2%).
A total of 30 (7.4%) patients developed acute 
leukemia, after a median time from RUX start of 13.1 
months; in 7 cases, RUX was suspended before the 
diagnosis of AL. The incidence rate of acute leukemia was 
1.3 per 100 patient-years from MF diagnosis and 3 per 100 
patient-years from RUX start.
Ninety-six (23.6%) patients died after a median 
time from RUX start of 15.4 months (range 1.5-56.7). 
Causes of death were, specifically: progression of 
myelofibrosis (37 patients, 38.5%), evolution into AL (16, 
16.7%), infections (13, 13.5%), heart disease (9, 9.4%), 
thrombotic/hemorrhagic events (8, 8.3%), allogeneic 
transplantation (4, 4.2%), second neoplasia (2, 2.1%), and 
other causes (7, 7.3%). Overall survival at 2 years from 
RUX start was 78.5%. Survival was not influenced by the 
type of MF diagnosis (primary versus secondary MF) (log-
rank p=0.53). As expected, OS at 2 years was significantly 
influenced by dynamic-IPSS (DIPSS) score [11] at 
RUX start (94.6%, 82.2% and 51.9% in intermediate-1, 
intermediate-2 and high risk patients, respectively, 
p<0.001).
Spleen response and baseline factors correlating 
with response
Spleen response was evaluable in 361 out of 408 
(88.5%) patients. A baseline splenomegaly palpable at 
<5 cm was not eligible for spleen response [9]. A total 
of 152 (42%) patients achieved a spleen response at 
any time by 3 years from RUX start. The overall rate of 
spleen responses was comparable in patients enrolled in 
the JUMP trial (45.6%) or treated in a “real-life” setting 
(36.7%) (p=0.09). At 3 and 6 months, the response was 
achieved by 26.6% and 34.9% of 361 and 327 evaluable 
patients, respectively. The rate of spleen reduction at least 
≥25% from baseline was significantly higher in patients 
with spleen palpable between 5 and 10 cm below LCM 
respect to patients with spleen >10 cm (79.9% vs 59.5%, 
p<0.001 at 3 months and 80.1% vs 59.7%, p<0.001 at 
6 months) (Figure 2A and 2B). In 79 (21.9%) cases, 
spleen became not palpable (Figure 2C). Figure 3 reports 
the correlations between main baseline clinical and 
laboratory features and subsequent spleen response at 
6 months. In univariate analysis, pre-treatment factors 
negatively correlating with spleen response were: IPSS 
risk intermediate-2/high (p=0.001), spleen palpable ≥10 
cm below LCM (p=0.001), transfusion-dependency 
(p=0.001), time interval between MF diagnosis and 
RUX start >2 years (p=0.011), anemia (Hb <10 g/dl, 
p=0.005), grade 3 marrow fibrosis (p=0.004), platelet 
count <200x109/l (p=0.002), and RUX starting dose <20 
mg BID (p=0.001) (Figure 3A). The diagnosis of PMF 
versus PET/PPV-MF was not significantly associated 
with spleen response, that was achieved by 25.7% 
and 26.9% of the patients, respectively (p=0.83). In 
multivariable regression logistic analysis, 5 variables 
remained significantly associated with a lower probability 
of spleen response: high/intermediate-2 IPSS risk 
(p=0.024); a large (≥10 cm below LCM) splenomegaly 
(p=0.017), transfusion dependency (p=0.022), platelet 
count <200x109/l (p=0.028), and a time-interval between 
MF diagnosis and RUX start >2 years (p=0.048) (Figure 
3B). We also evaluated the additional prognostic value 
of the “number” of predictive factors presented by each 
individual patient. Specifically, 64 (15.7%) patients 
presented one factor, 123 (30.1%) presented two factors, 
while 209 (52.1%) presented three or more baseline 
features among the five associated with worse response. 
The presence of three or more factors was significantly 
associated with lower probability of spleen response at 6 
months compared to patients carrying ≤2 factors (26.7% 
vs 49.6%, respectively; p<0.001).
Notably, a platelet count <200x109/l corresponded to 
a RUX starting dose lower than 20 mg BID. Accordingly, 
the rate of spleen response at 6 months was significantly 
higher in patients who started RUX at 20 mg BID (42.7% 
versus 26.8% in patients starting RUX with 10 or 15 mg 
BID, p=0.008, and 42.7% versus 21.6% in patients starting 
with 5 mg BID, p=0.017) (Supplementary Figure 1A). 
Also, patients titrated at average doses ≥10 mg BID during 
the first 12 weeks of therapy achieved more frequently a 
spleen response at 6 months compared to patients that 
received lower average doses (Supplementary Figure 1B).
By landmark analysis, overall survival was 
significantly better in patients achieving a spleen response 
at 6 months (Figure 4A). However, when the overall 
survival estimation was adjusted for the IPSS score 
(intermediate-1 vs intermediate-2/high) only a trend for 
statistical significance was observed (HR: 1.47, 95% CI: 
0.87–2.49, p=0.151) (Figure 4B).
Notably, the present analysis was confirmed when 
using the DIPSS instead of IPSS score. In multivariable 
analysis, intermediate 2/high DIPSS risk score remained 
negatively associated with the probability of achieving 
a spleen response at 6 months (OR=0.50, 95% CI 0.27-
0.94, p=0.032). By adjusting the survival curve for DIPSS, 
only the trend for statistical significance was observed 
(p=0.131).
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Figure 2: Spleen response. A baseline splenomegaly palpable at <5 cm was not eligible for spleen response. (A) Evaluable patients 
with a baseline spleen palpable between 5 and 10 cm below left costal margin. Spleen response: 100% decrease (not palpable spleen). (B) 
Evaluable patients with a baseline spleen palpable >10 cm below left costal margin. Spleen response: ≥50% decrease in palpable spleen 
length. (C) Best percent change from baseline in palpable spleen length at any time. Each bar represents data from an individual patient.
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Figure 3: Univariate (A) and multivariable (B) logistic regression models of baseline factors predictive for spleen response at 6 
months in patients treated with ruxolitinib. The area under the ROC curve was 0.69 and the H-L test reported a p value of 0.79. IPSS: 
International Prognostic Score System. TSS: Total Symptom Score. Fibrosis was evaluated according to the European Consensus 
Grading System [33].
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Symptoms response and baseline factors 
correlating with response
Overall, 359 (89.3%) out of 402 evaluable patients 
achieved a symptoms response by 3 years from therapy 
start (Supplementary Figure 2A). The overall rate of 
symptoms responses were comparable in patients enrolled 
in the JUMP trial (89.8%) or treated off study (87.9%) 
(p=0.54). At 3 and 6 months, 315 out of 402 (78.4%) 
and 294 out of 344 (85.5%) evaluable patients achieved 
a symptoms response. Notably, no significant correlation 
was found between RUX starting and 12-weeks titrated 
doses and the rate of symptoms responses at 6 months 
(Supplement Figure 2B and 2C, respectively).
In univariate analysis, patients with a Total Symptom 
Score (TSS) >20 and with a time-interval between 
Figure 4: Landmark analyses by spleen response at 6 months. A 6-month time after the initiation of therapy was selected as a 
landmark for conducting the analysis of survival by response. Only patients alive at 6 months were included in the analysis, separated into 
two response categories according to whether they have had a spleen response at that time-point. (A) Unadjusted survival rate calculated 
with Kaplan-Meier. Survival probability at 3 years from ruxolitinib start was 77.9% in patients achieving a spleen response at 6 months (blue 
line, n=114) and 68.4% in patients without a spleen response (yellow line, n=213) (Log-rank, p=0.034). (B) Overall survival estimation 
adjusted for IPSS score (HR: 1.47, 95% CI: 0.87–2.49, p=0.151). The dashed line on the x-axis represents the 6-months landmark point. 
SR: spleen response. NR: no response.
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MF diagnosis and RUX start longer than 2 years had a 
significantly lower probability of achieving a symptoms 
response at 6 months (70.1% vs 90.7% of patients with 
lower TSS, p<0.001; and 80.5% vs 89.2% of patients with 
time-interval <2 years, p=0.025, respectively) (Figure 5A).
The diagnosis of PMF versus PET/PPV-MF was not 
significantly associated with symptoms response, that was 
achieved by 85.9% and 85% of the patients, respectively 
(p=0.88). In multivariable analysis, a baseline TSS >20 
(OR: 0.25, 95% CI: 0.13–0.47; p<0.001) remained 
significant; a delay in treatment start showed only a trend 
for statistical significance (OR: 0.54, 95% CI: 0.29–1.02, 
p=0.056) (Figure 5B).
DISCUSSION
Ruxolitinib has significantly improved the 
therapeutic scenario of MF patients with splenomegaly 
and systemic symptoms. Nonetheless, approximately 
50% of patients do not achieve a satisfactory spleen and/or 
symptom response, and no predictors of response have yet 
Figure 5: Univariate (A) and multivariable (B) logistic regression models of baseline factors predictive for symptoms response at 6 months 
in patients treated with ruxolitinib. The area under the ROC curve was 0.70 and the H-L test reported a p value of 0.47. IPSS: International 
Prognostic Score System. TSS: Total Symptom Score.
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been identified to select patients who could benefit most 
from therapy.
The present study includes a large cohort of MF 
patients who received RUX for a considerably long 
period of time and were homogeneously evaluated 
according to the 2013 IWG-MRT criteria. In previous 
studies, using different response criteria, spleen response 
at 24 weeks varied significantly (COMFORT-1: 41.9%; 
COMFORT-2: 32%; JUMP: 56.9%; and ROBUST 54.2%) 
[5, 7, 9, 12]. We observed a rate of spleen responses of 
34.9% that was comparable to that (32%) observed in a 
previous retrospective study using the IWG-MRT criteria 
[13]. Conversely, our rate of symptoms responses was 
significantly higher than in previous studies (85.5% 
versus around 40-50% in COMFORT-1/COMFORT-2/
JUMP trials and 54.2% in the ROBUST study) [12]. 
Notably, our study included subjects that were treated 
at different hematology centers, some enrolled on an 
industry-sponsored study, others not. Nonetheless, spleen 
and symptom response rates were comparable in the two 
cohorts (Supplementary Table 1).
The first result of this study is that spleen response 
was inversely associated with MF severity, in terms 
of large splenomegaly, high/intermediate-2 IPSS risk, 
transfusion dependency and lower platelet count. 
Similarly, the probability to achieve a symptoms response 
was significantly lower in patients with higher burden of 
the disease (specifically, patients with baseline TSS >20). 
The relation between a more advanced disease and inferior 
responses may be expected, since patients with end-stage 
diseases are commonly more resistant to treatments. 
Indeed, the positive association between intermediate-1 
IPSS risk and spleen responses supports the results of 
the UK ROBUST study as well as those from real-world 
clinical evidence of ruxolitinib use in patients with lower 
risk MF [12, 14, 15]. It is acknowledged that, in absence 
of effective therapy, splenomegaly and systemic symptoms 
progressively worsen over time [4, 16]. Accordingly, 
in our study a time interval between MF diagnosis and 
ruxolitinib start longer than 2 years was significantly 
associated with decreased probability of spleen response. 
These data support the rationale for ongoing clinical 
studies evaluating if early treatment may achieve better 
therapeutic results.
Patients achieving a spleen response at 6 months 
had better survival compared to non-responders, although 
the difference did not maintain statistical significance 
after adjustment for the IPSS risk. Accordingly, a phase 
I/II study from MD Anderson Cancer Center and a recent 
pooled analysis of the COMFORT studies showed that 
spleen response was associated with better survival in 
RUX-treated patients, while a 5 dl increase from baseline 
in spleen size correlated with worse outcome [17, 18]. 
In this latter study, a positive correlation of greater 
spleen size reduction with a reduced risk of death was 
not observed in patients in the combined control group. 
Overall, further data are needed to clarify whether spleen 
reduction at 6 months might be considered as a surrogate 
marker for survival specific for RUX-treated patients.
The second result of this analysis is that RUX 
starting and titrated dose may influence spleen, but not 
symptoms, response. A trend for higher response rates 
in patients receiving titrated doses ≥10 mg BID was 
first highlighted in the ruxolitinib Phase 1-2 trial, and 
current expert recommendation suggest to maintain 
the maximum tolerated dose [19–22]. Additionally, 
ruxolitinib dose intensity, expressed as median cumulative 
dose, was found to be independently associated with 
spleen responses, together with higher JAK2V617F allele 
burden, in a recent study on 69 patients [13]. Here, RUX 
starting dose has been shown to significantly correlate 
with better responses irrespective of subsequent dose 
modifications. Nonetheless, patients that received stable 
doses of at least 10 mg BID during the first 12 weeks 
of therapy had better spleen response rates at 6 months. 
Particularly, patients titrated at 20 mg BID achieved the 
best response rates (42.3%). Overall, these data reinforces 
the recommendation to start with the higher possible dose 
according to baseline platelet count, and to maintain the 
maximum tolerated, at least during the first 3 months of 
treatment.
One of the limitations to our study is that, in absence 
of prospectively validated criteria, we adopted the 2013 
IWG-MRT criteria to assess responses. We acknowledge 
that these criteria are only a consensus statement, and may 
not be widely accepted. Second, marrow biopsies were 
not centrally reviewed and molecular analyses including 
driver and subclonal mutations [23–26] were not routinely 
and homogeneously performed in all Centers. The absence 
of extensive molecular evaluations, together with a 
preferential use of RUX in JAK2V617F-mutated patients, 
may also explain the non-usual distribution of driver 
mutations. Thus, the present study may not properly 
address the role of these pivotal biological data on 
responses to therapy. However, a higher degree in marrow 
fibrosis was correlated, in univariate analysis, with lower 
spleen response, supporting the known negative role of 
marrow fibrosis on MF prognosis [27–30].
In conclusion, a more advanced disease, a delay 
in ruxolitinib start and lower ruxolitinib doses identified 
patients with lower response rates. Taken together, these 
data may suggest the use of ruxolitinib at an early stage 
of the disease, when splenomegaly and/or systemic 
symptoms are milder and likely to be more responsive, 
possibly leading to a survival advantage.
MATERIALS AND METHODS
Patients and treatment
A multicenter observational study on WHO-defined 
MF was conducted in 18 Italian Hematology Centers. 
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Subjects were enrolled into the JAK Inhibitor rUxolitinib 
in Myelofibrosis Patients (JUMP) trial (ClinicalTrials.
gov Identifiers: NCT01493414) or treated off-study. Data 
were extracted from an electronic database that included 
consecutive patients treated with RUX from June 2011. 
Data cut-off was July 2016.
All treatments for MF, as well as baseline clinical/
laboratory features and outcome measures (including 
evolution into acute leukemia, death and spleen/symptoms 
responses) were recorded. Diagnosis of PMF and PET/
PPV-MF was made according to the WHO 2008 [31] or 
the IWG-MRT criteria [32], respectively. Histological 
examination was performed at local institutions; marrow 
fibrosis was graded according to the European Consensus 
Grading System [33]. Diagnosis of acute leukemia (AL) 
was made according to WHO criteria [34].
Spleen/symptoms responses and transfusion 
dependency were assessed at 3 and 6 months after 
treatement start and at last contact during ruxolitinib 
therapy. All responses were defined according to 2013 
IWG-MRT/ELN criteria [10]. Specifically, a spleen 
response was defined as disappearance of splenomegaly 
in patients with baseline splenomegaly palpable at 5-10 
cm below the LCM or as a decrease by ≥50% by palpation 
in case of a baseline splenomegaly palpable at >10 cm. 
A baseline splenomegaly that is palpable at <5 cm was 
not eligible for spleen response. Loss of response was 
defined as any increase in spleen size not meeting the 
initial response criteria. Due to its retrospective and 
observational nature, this study includes only evaluations 
performed in routine care; therefore, spleen responses did 
not receive confirmation by imaging techniques.
A symptoms response required a ≥50% reduction in 
the Myeloproliferative Neoplasm Symptom Assessment 
Form Total Symptom Score (MPN-SAF TSS) [35]. The 
MPN-SAF TSS was assessed by the patients themselves 
and this includes fatigue, concentration, early satiety, 
inactivity, night sweats, itching, bone pain, abdominal 
discomfort, weight loss, and fevers. Scoring is from 0 
(absent/as good as it can be) to 10 (worst imaginable/as 
bad as it can be) for each item. The MPN-SAF TSS is 
the summation of all the individual scores (0-100 scale) 
[35]. Transfusion dependency was also defined according 
to 2013 IWG-MRT criteria, as transfusions of at least 6 
units of RBC in the 12 weeks prior to ruxolitinib start, in 
the absence of bleeding or treatment-induced anemia.
The study was approved by the Institutional Review 
Board of each Institution and was conducted according to 
the Helsinki declaration.
Molecular and cytogenetic analysis
JAK2V617F allele-burden was assessed in granulocyte 
DNA by quantitative polymerase chain reaction (PCR)–
based allelic discrimination assay (ipsogen JAK2 
MutaQuant Kit) on 7900 HT Fast Real-Time-PCR System 
(Applied Biosystems) or by semi-quantitative PCR [36]. 
CALR exon 9 and MPL mutations were investigated as 
described elsewhere [37]. Chromosome banding analysis 
was performed on marrow cells by standard banding 
techniques according to the International System for 
Human Cytogenetic Nomenclature [38].
Statistical analysis
Continuous variables were expressed as median 
and ranges and categorical variables were presented as 
frequencies and percentages. Comparisons between groups 
were performed with Chi-square test and Two-sample 
Wilcoxon rank-sum (Mann-Whitney) test for categorical 
and continuous variables, respectively. Multivariable 
logistic regression analyses were conducted on variables 
with p<0.1 at univariate analysis.
Collinearity (multicollinearity) occurs when 
there are high correlations among predictor variables, 
leading to unreliable and unstable estimates of regression 
coefficients. To avoid this problem a common solution is 
to remove highly correlated predictors from the model, 
because they supply redundant information. Collinearity 
amongst variables was detected by means of Pearson 
correlation test and grade 3 fibrosis, hemoglobin <10 g/
dl, and RUX start dose <20 mg BID variables were found 
to be associated with the other factors; hence, they were 
excluded from the analysis.
Models building followed a backward-stepwise 
approach. For the multivariable logistic regression the 
model discrimination (area under the Receiver Operator 
Characteristic [ROC] curve) and calibration (Hosmer-
Lemeshow [H-L] test) were reported. Survival analysis 
was performed by means of Kaplan-Meier (KM) product-
limit estimate and differences between KM estimates 
were evaluated using the Log-rank test. To assess spleen 
response role as independent predictor of survival 
a multivariable Cox proportional hazard regression 
model was fitted to the data adjusting for the IPSS score 
(intermediate-1 vs intermediate-2/high). All tests were 
2-sided and a p value less than 0.05 was considered 
statistically significant. Analyses were performed with 
IBM SPSS Statistics 22 (IBM Analytics) and GraphPad 
Prism 6 (GraphPad Software).
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